At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 15 enrolled
Drug / intervention
Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
In Brief
A Phase 4 clinical trial evaluating Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) for Hepatitis C, Chronic and 3 related conditions. Completed, enrolled 15 participants across 4 sites.
Detailed Summary
This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have advanced cardiac disease or advanced lung disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartDec 2016
Primary CompletionApr 2019
Study CompletionJul 2019
TodayJul 2026
First PostedAug 8, 2016
Enrollment StartDec 1, 2016
Primary CompletionApr 11, 2019
Study CompletionJul 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.9 years ago
Interventions
Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)drug
1 pill once daily of SOF/LDV FDC